BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 7578520)

  • 1. Kinetics of minimal residual disease during induction/consolidation therapy in standard-risk adult B-lineage acute lymphoblastic leukemia.
    Scholten C; Födinger M; Mitterbauer M; Laczika K; Mitterbauer G; Haas OA; Knöbl P; Schwarzinger I; Thalhammer R; Purtscher B
    Ann Hematol; 1995 Oct; 71(4):155-60. PubMed ID: 7578520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor delta gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia.
    Steward CG; Goulden NJ; Katz F; Baines D; Martin PG; Langlands K; Potter MN; Chessells JM; Oakhill A
    Blood; 1994 Mar; 83(5):1355-62. PubMed ID: 8118037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.
    Dibenedetto SP; Lo Nigro L; Mayer SP; Rovera G; Schilirò G
    Blood; 1997 Aug; 90(3):1226-32. PubMed ID: 9242556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of clonal immunoglobulin heavy chain and I cell receptor gamma gene rearrangements during progression of childhood acute lymphoblastic leukemia.
    Marshall GM; Kwan E; Haber M; Brisco MJ; Sykes PJ; Morley AA; Toogood I; Waters K; Tauro G; Ekert H
    Leukemia; 1995 Nov; 9(11):1847-50. PubMed ID: 7475273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Childhood B lineage acute lymphoblastic leukemia clonality study by the polymerase chain reaction.
    Scrideli CA; Simoes AL; Defavery R; Bernardes JE; Duarte MH; Tone LG
    J Pediatr Hematol Oncol; 1997; 19(6):516-22. PubMed ID: 9407937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal residual disease in acute lymphoblastic leukaemia--PCR analysis of immunoglobulin gene rearrangements.
    Cole-Sinclair M; Foroni L; Wright F; Mehta A; Prentice HG; Hoffbrand AV
    Leuk Lymphoma; 1993; 11 Suppl 2():49-58. PubMed ID: 8124233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of minimal residual disease in childhood acute lymphoblastic leukemia patients by polymerase chain reaction analysis of multiple clone-specific or malignancy-specific gene markers.
    Kuang S; Gu L; Dong S; Cao Q; Xu C; Huang W; Su XY; Huang QH; Xie JX; Chen SJ; Chen Z
    Cancer Genet Cytogenet; 1996 Jun; 88(2):110-7. PubMed ID: 8640718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
    Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
    Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome.
    Gruhn B; Hongeng S; Yi H; Hancock ML; Rubnitz JE; Neale GA; Kitchingman GR
    Leukemia; 1998 May; 12(5):675-81. PubMed ID: 9593264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
    Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
    N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
    Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
    J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitation of leukemia clone-specific antigen gene rearrangements by a single-step PCR and fluorescence-based detection method.
    Mayer SP; Giamelli J; Sandoval C; Roach AS; Fevzi Ozkaynak M; Tugal O; Rovera G; Jayabose S
    Leukemia; 1999 Nov; 13(11):1843-52. PubMed ID: 10557060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of detection of monoclonality in remission marrow in acute lymphoblastic leukemia in childhood. Australian and New Zealand Children's Cancer Study Group.
    Brisco MJ; Condon J; Hughes E; Neoh SH; Nicholson I; Sykes PJ; Tauro G; Ekert H; Waters K; Toogood I
    Leukemia; 1993 Oct; 7(10):1514-20. PubMed ID: 8412313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCR detection of clonal IgH and TCR gene rearrangements at the end of induction as a non-remission criterion in children with ALL: comparison with standard morphologic analysis and risk group classification.
    Scrideli CA; Queiroz RG; Bernardes JE; Valera ET; Tone LG
    Med Pediatr Oncol; 2003 Jul; 41(1):10-6. PubMed ID: 12764736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.
    Chan DW; Liang R; Kwong YL; Chan V
    Am J Hematol; 1996 Jul; 52(3):171-7. PubMed ID: 8756082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgH/TCR delta PCR oligonucleotide liquid hybridization, a fast and sensitive assay for monitoring minimal residual disease in childhood B-precursor ALL.
    Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; von dem Borne AE; van der Schoot CE
    Leukemia; 1995 Jan; 9(1):216-22. PubMed ID: 7845021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymerase chain reaction-single-strand conformational polymorphism analysis of antigen receptor rearrangements in monitoring therapeutic effect in childhood ALL.
    Thunberg U; Sällström J; Frost BM; Lönnerholm G; Sundström C
    Diagn Mol Pathol; 1998 Jun; 7(3):146-51. PubMed ID: 9836069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphoblastic leukemia.
    Ito Y; Wasserman R; Galili N; Reichard BA; Shane S; Lange B; Rovera G
    J Clin Oncol; 1993 Mar; 11(3):546-53. PubMed ID: 8445430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal residual disease quantification in childhood acute lymphoblastic leukemia by real-time polymerase chain reaction using the SYBR green dye.
    Li AH; Forestier E; Rosenquist R; Roos G
    Exp Hematol; 2002 Oct; 30(10):1170-7. PubMed ID: 12384148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.